Role of Presenilin1 and Beta-Catenin Interaction In Vivo
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
A2000019
Summary
The PS1 gene is expressed throughout the bodies of all mammals. The complete loss of the PS1 gene in laboratory mice causes a lethal condition in mouse embryos. However, specialized mouse strains that have been engineered to express the human PS1 in the central nervous system, but not elsewhere, can survive. Dr. Zheng has found that these mice develop epidermal hyperplasia and neoplasm, or skin cancer, and that the skin cancer phenotype is similar to that found for transgenic mice that exhibit overactivity in the molecule Beta-Catenin. Dr. Zheng has proposed that this molecule interacts with PS1 and plays a role in cell signaling. In this study, she is attempting to determine the molecular mechanisms of PS1 in the growth of tumors. Then the discovery will be utilized to generate specific mutations in PS1 to further examine its interaction with Beta-Catenin. Because this technique allows the survival of mice whose expression of PS1 has been inhibited, it is hoped that a better understanding of the role of PS-1 in adult tissues will be attained.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD